252 related articles for article (PubMed ID: 15809436)
1. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.
Tsvetkov P; Asher G; Reiss V; Shaul Y; Sachs L; Lotem J
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5535-40. PubMed ID: 15809436
[TBL] [Abstract][Full Text] [Related]
2. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
[TBL] [Abstract][Full Text] [Related]
3. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
4. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53.
Gong X; Kole L; Iskander K; Jaiswal AK
Cancer Res; 2007 Jun; 67(11):5380-8. PubMed ID: 17545619
[TBL] [Abstract][Full Text] [Related]
5. NQO1 stabilizes p53 through a distinct pathway.
Asher G; Lotem J; Kama R; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):3099-104. PubMed ID: 11867746
[TBL] [Abstract][Full Text] [Related]
6. Curcumin stabilizes p53 by interaction with NAD(P)H:quinone oxidoreductase 1 in tumor-derived cell lines.
Patiño-Morales CC; Soto-Reyes E; Arechaga-Ocampo E; Ortiz-Sánchez E; Antonio-Véjar V; Pedraza-Chaverri J; García-Carrancá A
Redox Biol; 2020 Jan; 28():101320. PubMed ID: 31526948
[TBL] [Abstract][Full Text] [Related]
7. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
[TBL] [Abstract][Full Text] [Related]
8. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1.
Asher G; Lotem J; Cohen B; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1188-93. PubMed ID: 11158615
[TBL] [Abstract][Full Text] [Related]
9. Dual pathways of p53 mediated glucolipotoxicity-induced apoptosis of rat cardiomyoblast cell: activation of p53 proapoptosis and inhibition of Nrf2-NQO1 antiapoptosis.
Wang HJ; Lee EY; Han SJ; Kim SH; Lee BW; Ahn CW; Cha BS; Lee HC
Metabolism; 2012 Apr; 61(4):496-503. PubMed ID: 22154326
[TBL] [Abstract][Full Text] [Related]
10. Ell3 stabilizes p53 following CDDP treatment via its effects on ubiquitin-dependent and -independent proteasomal degradation pathways in breast cancer cells.
Ahn HJ; Kim KS; Shin KW; Lim KH; Kim JO; Lee JY; Kim J; Park JH; Yang KM; Baek KH; Ko JJ; Park KS
Oncotarget; 2015 Dec; 6(42):44523-37. PubMed ID: 26540344
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.
Nolan KA; Scott KA; Barnes J; Doncaster J; Whitehead RC; Stratford IJ
Biochem Pharmacol; 2010 Oct; 80(7):977-81. PubMed ID: 20599803
[TBL] [Abstract][Full Text] [Related]
12. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
13. Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
Buranrat B; Prawan A; Kukongviriyapan U; Kongpetch S; Kukongviriyapan V
World J Gastroenterol; 2010 May; 16(19):2362-70. PubMed ID: 20480521
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells.
Yu H; Gao HY; Guo H; Wang GZ; Yang YQ; Hu Q; Liang LJ; Zhao Q; Xie DW; Rao Y; Zhou GB
Acta Pharmacol Sin; 2022 Mar; 43(3):692-702. PubMed ID: 34035487
[TBL] [Abstract][Full Text] [Related]
15. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73.
Asher G; Tsvetkov P; Kahana C; Shaul Y
Genes Dev; 2005 Feb; 19(3):316-21. PubMed ID: 15687255
[TBL] [Abstract][Full Text] [Related]
16. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector.
Dinkova-Kostova AT; Talalay P
Arch Biochem Biophys; 2010 Sep; 501(1):116-23. PubMed ID: 20361926
[TBL] [Abstract][Full Text] [Related]
17. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1.
Asher G; Bercovich Z; Tsvetkov P; Shaul Y; Kahana C
Mol Cell; 2005 Mar; 17(5):645-55. PubMed ID: 15749015
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.
Scott KA; Barnes J; Whitehead RC; Stratford IJ; Nolan KA
Biochem Pharmacol; 2011 Feb; 81(3):355-63. PubMed ID: 20970406
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
20. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.
Siegel D; Kepa JK; Ross D
PLoS One; 2012; 7(9):e44861. PubMed ID: 22984577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
